CheckMate-8HW — Nivolumab plus Ipilimumab versus Chemotherapy in First-Line MSI-H/dMMR Metastatic Colorectal Cancer

Phase 3 · 2024 · Colorectal Cancer

Design

Randomized nivolumab + ipilimumab versus chemotherapy (and versus nivolumab monotherapy) in first-line and later settings.

Population

MSI-H or mismatch-repair-deficient metastatic colorectal cancer.

Primary Endpoint

progression-free survival (PFS)

Key Result

Nivolumab + ipilimumab dramatically improved PFS versus chemotherapy in first-line MSI-H/dMMR mCRC (HR 0.21; 2-year PFS 72% vs 14%).

Guideline Impact

First-line MSI-H/dMMR metastatic colorectal cancer